Skip to main content

Table 2 A gender-based comparison of descriptive study characteristics

From: Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda

Characteristic Females Males
Controls Cases Total Controls Cases Total
n (col %) n (col %) n (col %) n (col %) n (col %) n (col %)
Type of Second-line drug
Alluvia 143(94.7) 25(89.3) 168(93.9) 98(94.2) 46(80.7) 144(89.4)
Atazanavir 5(3.3) 3(10.7) 8(4.5) 3(2.9) 1(1.8) 4(2.5)
Other PIµ 3(2.0) 0(0) 3(1.7) 3(2.9) 10(17.5) 13(8.1)
Total 151(100) 28(100) 179(100) 104(100) 57(100) 161(100)
TB treatment ψ
No 146(97.3) 23(82.1) 169(94.9) 100(97.1) 48(84.2) 148(92.5)
Yes 4(2.7) 5(17.9) 9(5.1) 3(2.9) 9(15.8) 12(7.5)
Total 150(100) 28(100) 178(100) 103(100) 57(100) 160(100)
Year of ART initiation
Before 2001 6(4.0) 2(7.1) 8(4.5) 1(1.0) 21(36.8) 22(13.7)
2001–2005 91(60.3) 15(53.6) 106(59.2) 79(76.0) 26(45.6) 105(65.2)
2006–2010 44(29.1) 9(32.1) 53(29.6) 20(19.2) 10(17.5) 30(18.6)
2011–2015 10(6.6) 2(7.1) 12(6.7) 4(3.8) 0 (0) 4(2.5)
Total 150(100) 28(100) 179(100) 104(100) 57(100) 161(100)
Type of First-line drug
NNRTI based 129(85.4) 22(78.6) 151(84.4) 88(84.6) 44(77.2) 132(82.0)
NON-NNRTI 22(14.6) 6(21.4) 28(15.6) 16(15.4) 13(22.8) 29(18.0)
Total 151(100) 28(100) 179(100) 104(100) 57(100) 161(100)
Other comorbidities§
No 139(93.3) 28(100) 167(94.4) 87(83.7) 48(84.2) 135(83.9)
Yes 10(6.7) 0(0) 10(5.6) 17(16.3) 9(15.8) 26(16.1)
Total 149(100) 28(100) 177(100) 104(100) 57(100) 161(100)
No 139(93.3) 28(100) 167(94.4) 87(83.7) 48(84.2) 135(83.9)
Yes 10(6.7) 0(0) 10(5.6) 17(16.3) 9(15.8) 26(16.1)
Total 149(100) 28(100) 177(100) 104(100) 57(100) 161(100)
Age at the start of 2nd line ART: median (IQR) 36 (31–41) 35.5(31.5–38) 36(31–41) 43(35–49) 39(31–48) 42(33–49)
CD4 at the start of 2nd line ART: median (IQR) 155(77–253) 65.5(15–135) 137(62–243) 101.5(37–230) 78.5(28.5–205) 93(34–205)
VL at start of 2nd line ART: median (IQR)¥ 37,706(12,880–135,248) 233,700(51,014–547,922) 50,305.5(1453.5–162,197) 54,588(14,444–135,859) 139,901(72,510–645,978) 76,115(21,919.5–250,702)
Duration on 1st line: median (IQR) 4(2–5) 3(1.5–4) 3(2–5) 3(2–5) 4(2–6) 3(2–6)
  1. §Missing data on two observations, ψ Missing data on one observation, ¥ Missing data on 128 observations, TB: tuberculosis, VL: Viral Load, IQR: Interquartile Range, ART: Antiretroviral Therapy, ∞Non-NRTI: triple nucleosides, µ “other PI”: saquinavir and nelfinavir